Tosulfoxacin Treatment of Chlamydia Trachomatis Infection of the Uterine Cervix

Keiichi Takahashi; Kyoko Shioda; Ikuko Yokoo; Yoshiharu Yamada; Tomoyuki Miyakawa; Makoto Izuta; Kodo Sato

doi:10.1007/BF02490035

Tosulfoxacin Treatment of Chlamydia Trachomatis Infection of the Uterine Cervix

J Infect Chemother. 1997;3(4):202-204. doi: 10.1007/BF02490035. Epub 2014 Apr 5.

Authors

Keiichi Takahashi¹, Kyoko Shioda¹, Ikuko Yokoo¹, Yoshiharu Yamada¹, Tomoyuki Miyakawa¹, Makoto Izuta¹, Kodo Sato¹

Affiliation

¹ Department of Obstetrics and Gynecology, Toranomon Hospital, 2-2-2-Toranomon, Minato-ku, 105, Tokyo, Japan.

PMID: 29681343
DOI: 10.1007/BF02490035

Abstract

In vivo efficacy of tosufloxacin (TFLX) for treatment of Chlamydia trachomatis cervical infection in women was evaluated by enzyme immunoassay. The short term (within 31 days of treatment) response rates with a dosage of 150mg orally 3 times daily were 100% (54/54) with 14 days of treatment and 97% (38/39) with 7 days of treatment. Subjective symptoms such as lower abdominal pain, vaginal discharge, or atypical bleeding were observed in 76 (82%) of the 93 patients. After treatment, symptoms improved in 75 (99%) of 76 patients. Two of 34 patients (5.9%) showed positive results in the long interval tests (1 to 18 months after treatment). Three (2.3%) of 131 patients needed to be changed from TFLX to other drugs due to side effects (eczema, face edema, urticaria). TFLX was effective and patients showed high compliance for treatment of cervical C. trachomatis infection.

Keywords: Chlamydia trachomatis; tosufloxacin; treatment.